Exact (EXAS) Gains 6.96% for June 23

Equities Staff  |

Exact Sciences Corp. (NASDAQ:EXAS) stock was among today's market movers, finishing trading higher 6.96% to $42.24 on June 23.

1,885,463 shares traded hands while the 30-day daily average of 2,233,081 shares.

The company's stock has risen 49.26% so far in 2022.

Exact shares have traded in a range between $35.34 and $133.99 over the past twelve months.

The company expects its next earnings on 2022-07-27.

For technical charts, analysis, and more on Exact visit the company profile.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer.

To get more information on Exact Sciences Corp. and to follow the company's latest updates, you can visit the company's profile page here: Exact Sciences Corp.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content